Benefits of early aggressive immunomodulatory therapy (tocilizumab and methylprednisolone) in COVID-19: Single center cohort study of 685 patients.
Luis BM, Miguel MB, Pedro DL, David IP, Itziar A, Ana GH, Enrique IJ, María LV, Noelia TF, Julio César BB, Marta UI, Rodrigo SL, María CB, Andrés LM, Javier MI, Juan Pablo GM, Gerardo HF, Carolina NF, Jorge BL, María FR, Fernando CT, Sergio OE, Lourdes FC, María GE, Gregoria ML, Adolfo SR, José Antonio FR; HUBU-COVID-19 group.
Luis BM, et al. Among authors: ana gh.
J Transl Autoimmun. 2021;4:100086. doi: 10.1016/j.jtauto.2021.100086. Epub 2021 Feb 12.
J Transl Autoimmun. 2021.
PMID: 33615209
Free PMC article.
Review.